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Purpose or Objective: The use of postoperative radiotherapy 
(RT) in patients (pts) at risk for local recurrence is well 
established for many tumours. The postoperative subgroup of 
the AIRO Working Group on Prostate RT carried out a multi-
institutional prospective study to evaluate the impact of 
Adjuvant RT (PORT) and Salvage RT (SART) on biochemical 
outcomes in prostate cancer pts. 
 
Material and Methods: Between January 2002 and December 
2003, data of 440 pts (mean age: 65 years, range 42-81) 
treated with radical prostatectomy (RP) were collected by 14 
Italian RT Departments. Of the 411 pts available for the 10 
year analysis (median follow up: 111 months), 284 (69.1%) 
received PORT (started <6 months after RP) and 127 
underwent SART because of increasing PSA level after having 
been undetectable or persistently elevated PSA (> 6 months 
after RP). Gleason Score (GS) > 7 and positive surgical 
margins (SM+) have been shown by 69% pts and 74.5% 
respectively; 76.5% presented locally advanced disease (pT3-
4), 27 (6.7%) positive pelvic nodes; 163 pts (40.2%) revealed 
seminal vesicles invasion (SVI). All pts received RT to the 
prostatic fossa (mean dose of 67.8 Gy, range: 60-76). Pelvic 
RT was delivered to 111 pts (27%). Androgen deprivation (AD) 
was prescribed to 47,3% pts. Among 127 SART pts, pre-RT PSA 
level was 1 ng/mL or less in 56 pts (44,1%). 
 
Results: Ten year analysis shows that 259 pts are disease free 
and 331 are still alive. 10 year (10-y) overall survival and 
biochemical control (BC) rate are 75.9% and 57.8% 
respectively. On univariate analysis, PORT versus SART, SVI 
and GS > 7 significantly influenced 10-y BC rate: 62.7% in 
PORT group versus 45.6% SART one (p = 0.003), 56.9% in pts 
with SVI versus 65.6% pts without SVI (p < 0.001), 52.5% if GS 
> 7 and 69.8% if GS < 7 (p= 0.003). SM+, pathological T and N 
stages, AD or pelvic RT had no impact on biochemical 
recurrence rate. SVI and PORT versus SART were variables 
associated with BC on multivariate analysis. Only pre-RT PSA 
level significantly influenced disease free survival in SART 
setting: when the pre-RT PSA was 1 ng/mL or less, 59.8% pts 
were disease free at 10-y compared with 33.5% of those 
treated at PSA levels greater than 1 ng/mL (p= 0.017). 
 
Conclusion: Pts in PORT group, pts without SVI and with GS < 
7 show better BC rates . Postoperative RT delivered in high 
risk prostate cancer patients can reduce the impact of other 
common unfavourable prognostic factors (pT stage, positive 
surgical margins). Early referral for SART offers better 
disease control after radical prostatectomy. This prospective 
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Purpose or Objective: A bladder-preserving strategy, 
combining transurethral resection of the bladder tumor (TUR-
B) with radiochemotherapy, results in a long-term overall 
survival comparable to cystectomy. However, such a strategy 
is mostly applied to elderly or unfit patients, but their 
medical status regularly contraindicates chemotherapy. This 
leaves the combination of TUR-B and radical radiotherapy as 
the only treatment option. For this vulnerable patient group, 
reduction of toxicity is of additional importance, which could 
be obtained by more conformal treatment plans. It was our 
aim to retrospectively analyze the treatment outcome and 
associated toxicity of both conformal and intensity-
modulated radiotherapy (IMRT) using a tumor boost, for 
locally advanced bladder cancer in patients not suitable for 
cystectomy. 
 
Material and Methods: 119 patients with T1-4 N0-1 M0 
bladder cancer were analyzed retrospectively. Median age 
was 80 years. Patient and treatment characteristics can be 
found in Table 1. Treatment consisted of either a conformal 
box technique or IMRT. Patients were treated with 40 Gy in 
20 fractions to the elective treatment volumes, and a daily 
boost of 0.75 Gy to the tumor. This resulted in a tumor boost 
of either 55 Gy or 60 Gy, the latter in case expected toxicity 
allowed delivery of two additional 2.5 Gy fractions to the 
tumor. Cystoscopic placement of fiducial markers aided in 
tumor delineation. To evaluate response, a cystoscopy was 
performed two months after treatment and thereafter every 
six months. To assess toxicity, patients were seen by their 
oncologist every week during the treatment course, and 
thereafter with 1-12 month intervals until up to 5 years after 
treatment. Toxicity was scored according to the CTCAE 
version 4, with acute toxicity defined as occurring during 
treatment or within the first three months thereafter. The 
Kaplan-Meier method was used to estimate survival and 
locoregional control. Possible predictors for survival were 
examined in univariate Cox proportional hazard regression 
analyses. Differences in toxicity between IMRT or conformal 
radiotherapy were tested using χ2 tests.  
 
 
Results: At 3 months, a complete response was seen in 87% 
of patients. 3-year overall survival was 44%, with a 
locoregional control rate of 72% at three years (Figure 1). 
Including pelvic lymph nodes in the elective field increased 
survival significantly (hazard ratio: 0.58, p = 0.04). Late 
toxicity was low, with urinary and intestinal toxicity grades ≥ 
2 of 14% and 5%, respectively. IMRT reduced late intestinal 
toxicity grade ≥ 1 from 24% to 7% (p=0.04), as well as acute 
intestinal toxicity grade ≥ 2 (from 36% to 12%, p = 0.03). 




Conclusion: Radical radiotherapy is feasible and effective for 
elderly or unfit patients. Three-year locoregional control 
after radical radiotherapy using a boost technique was 72%, 
with low rates for late urinary and intestinal toxicity. Early 
and late toxicity rates were reduced by using IMRT. 
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Purpose or Objective: We conducted a phase I trial of 
Gemcitabine (GEM) with concomitant 3D-Conformal 
Radiotherapy (3D-CRT) and Cisplatin (CDDP) in patients with 
muscle-invasive bladder cancer who were ineligible for 
surgery or refused organ loss. 
 
Material and Methods: 28 patients with transitional cell 
carcinoma, cT2(n=14), cT3(n=8), T4a(n=6), cN0-1, M0, 
median age 70.5 years were included after maximal 
transurethral resection. 3D-CRT was administered with a 
18MV Linac, 1.8Gy/Fr, 5d/week up to 64.80Gy. The GEM 
starting dose of 40mg/m2/week was increased by 40mg/m2 
increments to 2 levels (80 and 120mg/m2/week) in cohorts of 
6 patients. The standard dose of CDDP was 25mg/m2/week 
given 2 days after GEM infusion. Both drugs were given 30 to 
60min before irradiation 
 
Results: All patients were evaluated for toxicity which was 
evaluated according to the Common Toxicity Criteria and the 
RTOG/EORTC Score. The DLTs (Dose Limiring Toxicities) were 
defined as hematologic grade >3 or Non-hematologic grade 3 
events, as Abdominal pain/Diarrhea (Proctitis), 
Dysuria/Urinary frequency (Cystitis), Fatigue/Asthenia, not 
resolving tro grade 1/2 within 2 days or necessitating the 
interruption of RT for >1 week, in more than 3 of 6 patients 
in each cohort. The GEM dose immediately before the level 
at which the DLT was observed was defined as the Maximum 
Tolerated Dose (MTD). In 6 patients accrued to GEM dose 
40mg/m2/week no grade 3 toxicities were seen. From 6 
patients given 80mg/m2/week of GEM, 2 had episodes of 
grade 3 bladder toxicity, 3 General Weakness and 2 
presented with grade 3 hematological sequelae. From 6 
patients accrued to GEM dose 120mg/m2/week, 4 had 
episodes of grade 3 neutropenia and/or thrombocytopenia 
and 3 showed grade 3 fatigue/malaise. In 4 patients 
treatment was interrupted for more than 1 week. The 2-year 
locoregional failure rate was 28% (8/28). 12 of 28 (42%) 
patients are alive with no evidence of disease progression, 8 
patients developed M1 disease and 5 died from this. 
 
Conclusion: GEM given synchronously with 3D-CRT is well 
tolerated as a bladder preservation schema. The MTD was 
defined at 80mg/m2/week combined to CDDP and merits 
evaluation in phase II/III trials. 
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Purpose or Objective: Wide surgical excision is the standard 
treatment for angiosarcoma of the scalp, but it is often 
difficult to completely excise because of the invasive nature 
and typical multifocal spread of the tumor. Furthermore, 
many patients are medically inoperable because of old age or 
coexisting disease. Therefore, we investigated the outcome 
of radiation therapy with total scalp irradiation for 
angiosarcoma of the scalp. 
 
Material and Methods: Seventeen patients with 
angiosarcoma of the scalp underwent radiation therapy with 
total scalp irradiation with curative intent. Their median age 
at the time of irradiation was 77 (range, 57–89) years. Four of 
the 17 patients had tumor invasion into the deep organs, 
including the skull in three and the temporal muscle in one. 
Four patients had cervical lymph node metastases, but none 
had distant metastases. A median initial dose of 50 Gy in 25 
fractions was delivered to the entire scalp. Two pairs of 
lateral X-ray and electron fields were used for total scalp 
irradiation: 4–6 MV X-rays were delivered through bilaterally 
opposed ports to the central scalp from the frontal eminence 
to the suboccipital region, to a depth of 10 mm inside the 
skull, and 5–9 MeV electrons were delivered through single 
ports to the bilateral temporal scalp. Subsequently, local 
radiation boost to the tumor sites achieved a median total 
dose of 70 Gy in 35 fractions. 
Results: All irradiated tumors disappeared or were markedly 
reduced after radiation therapy; the objective response rate 
was 100%. However, 14 of the 17 patients developed 
recurrences during the median follow-up period of 14 months 
after radiation therapy; seven had recurrences in the scalp, 
including primary tumor progression in two patients and new 
disease in five, and 12 patients developed distant 
metastases. The two patients with primary tumor progression 
originally had tumor invasion into the skull and temporal 
muscle, and received a total radiation dose of 70 Gy in 35 
fractions. The primary progression-free, scalp relapse-free, 
